Thiopurine Analogue Inhibitors of Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease,a Deubiquitinating and deISGylating Enzyme

Abstract

In the search for effective therapeutics against severe acute respiratory syndrome (SARS), 6-mercaptopurine (6MP) and 6-thioguanine (6TG) were found to be specific inhibitors for the SARS—coronavirus (CoV) papain-like protease (PLpro), a cysteine protease with deubiquitinating and deISGylating activity. 6MP and 6TG have long been used in cancer chemotherapy for treatment of acute lymphoblastic or myeloblastic leukaemia. Development and optimization of 6MP and 6TG will not only be important for anti-viral studies, but also for further elucidating the biological functions of cellular deubiquitinating enzymes (DUBs) and deISGylating enzymes. So far, several crystal structures of cellular DUBs have been solved. Structure comparison has been carried out to search for DUBs with a similar structure to that of PLpro, and we have tried to dock 6MP and 6TG into these DUBs to investigate the potential use of 6MP and 6TG as cellular DUB inhibitors. The best docking score and binding energy for 6MP and 6TG is against ubiquitin-specific protease (USP)14, suggesting that 6MP and 6TG are potential inhibitors of USP14. Finding new usages for old drugs will speed up the process of drug discovery and substantially reduce the cost of drug development.

References

Chou

Chien

Han

. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem Pharmacol 2008; 75: 1601–1609.

Elion

. The purine path to chemotherapy. Science 1989; 244: 41–47.

Pui

Evans

. Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605–615.

O'Connor

Roth

. Finding new tricks for old drugs: An efficient route for public-sector drug discovery. Nat Rev Drug Discov 2005; 4: 1005–1014.

Harcourt

Jukneliene

Kanjanahaluethai

. Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol 2004; 78: 13600–13612.

Han

Chang

Juo

. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): Expression, purification, characterization, and inhibition. Biochemistry 2005; 44: 10349–10359.

Karran

Attard

. Thiopurines in current medical practice: Molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8: 24–36.

Barretto

Jukneliene

Ratia

. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 2005; 79: 15189–15198.

Lindner

Fotouhi-Ardakani

Lytvyn

. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 2005; 79: 15199–15208.

10.

Lindner

Lytvyn

. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch Biochem Biophys 2007; 466: 8–14.

11.

Sadler

Williams

. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8: 559–568.

12.

Ritchie

Hahn

Kim

. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 2004; 10: 1374–1378.

13.

Osiak

Utermöhlen

Niendorf

Horak

Knobeloch

. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signalling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol Cell Biol 2005; 25: 6338–6345.

14.

Lenschow

Giannakopoulos

Gunn

. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 2005; 79: 13974–13983.

15.

Lenschow

Lai

Frias-Staheli

. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 2007; 104: 1371–1376.

16.

Ratia

Saikatendu

Santarsiero

. Severe acute respiratory syndrome coronavirus papain-like protease: Structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci U S A 2006; 103: 5717–5722.

17.

Hochstrasser

. Ubiquitin-dependent protein degradation. Annu Rev Genet 1996; 30: 405–439.

18.

Chung

Baek

. Deubiquitinating enzymes: Their diversity and emerging roles. Biochem Biophys Res Commun 1999; 266: 633–640.

19.

Wilkinson

. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 1997; 11: 1245–1256.

20.

Nijman

Luna-Vargas

Velds

. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773–786.

21.

Nicholson

Marblestone

Butt

Mattern

. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007; 3: 191–199.

22.

Guédat

Colland

. Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem 2007; 8 Suppl 1: S14.

23.

Love

Catic

Schlieker

Ploegh

. Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol 2007; 3: 697–705.

24.

Hershko

Rose

. Ubiquitin-aldehyde: A general inhibitor of ubiquitin-recycling processes. Proc Natl Acad Sci U S A 1987; 84: 1829–1833.

25.

Pickart

Cohen

. Proteasomes and their kin: Proteases in the machine age. Nat Rev Mol Cell Biol 2004; 5: 177–187.

26.

Catic

Fiebiger

Korbel

Blom

Galardy

Ploegh

. Screen for ISG15-crossreactive deubiquitinases. PLoS One 2007; 2: e679.

27.

Malakhov

Malakhova

Kim

Ritchie

Zhang

. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J Biol Chem 2002; 277: 9976–9981.

28.

Frias-Staheli

Giannakopoulos

Kikkert

. Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe 2007; 2: 404–416.

29.

Lindner

. Deubiquitination in virus infection. Virology 2007; 362: 245–256.

30.

Krissinel

Henrick

. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr 2004; 60: 2256–2268.

31.

. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 2002; 111: 1041–1054.

32.

Song

. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J 2005; 24: 3747–3756.

33.

Renatus

Parrado

D'Arcy

. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 2006; 14: 1293–1302.

34.

Komander

Barford

. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem J 2008; 409: 77–85.

35.

Komander

Lord

Scheel

. The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module. Mol Cell 2008; 29: 451–464.

36.

Avvakumov

Walker

Xue

. Amino-terminal dimerization, NRDP1-rhodanese interaction, and inhibited catalytic domain conformation of the ubiquitin-specific protease 8 (USP8). J Biol Chem 2006; 281: 38061–38070.

37.

Schlieker

Weihofen

Frijns

Kattenhorn

Gaudet

Ploegh

. Structure of a herpesvirus-encoded cysteine protease reveals a unique class of deubiquitinating enzymes. Mol Cell 2007; 25: 677–687.

38.

Johnston

Larsen

Cook

Wilkinson

Hill

. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 A resolution. EMBO J 1997; 16: 3787–3796.

39.

Nicholson

Leach

Goldenberg

. Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities. Protein Sci 2008; 17: 1035–1043.

40.

Roberts

Lamirande

Vogel

. Animal models and vaccines for SARS-CoV infection. Virus Res 2008; 133: 20–32.

41.

Chernova

Allen

Wesoloski

Shanks

Chernoff

Wilkinson

. Pleiotropic effects of Ubp6 loss on drug sensitivities and yeast prion are due to depletion of the free ubiquitin pool. J Biol Chem 2003; 278: 52102–52115.